SCHEDULE: Vanguard Group Reports Zero Beneficial Ownership in Tarsus

The Vanguard Group has filed an amended Schedule 13G, reporting zero beneficial ownership in Tarsus Pharmaceuticals Inc. following an internal realignment.

Summary

• The Vanguard Group filed an Amendment No. 2 to its Schedule 13G for Tarsus Pharmaceuticals Inc. Common Stock.
• The filing reports 0 shares beneficially owned by The Vanguard Group, representing 0% of the class of Common Stock.
• This change in reported ownership is attributed to an internal realignment within The Vanguard Group that occurred on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of The Vanguard Group, Inc. will now report beneficial ownership separately (on a disaggregated basis) in reliance on SEC Release No. 34-39538.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these disaggregated subsidiaries and/or business divisions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, procedural filing reflecting an internal organizational change by The Vanguard Group rather than a change in investment thesis regarding Tarsus Pharmaceuticals Inc.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding Tarsus Pharmaceuticals Inc.'s operations or financial performance.

Management Comments

• On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment.
• In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release.
• These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment.
• Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.

Industry Context

StockSavvy.ai notes that institutional investors like Vanguard frequently adjust their internal reporting structures or reallocate holdings among various internal entities. Such changes in reported beneficial ownership by the parent entity do not necessarily indicate a change in the overall investment strategy or total holdings by the broader institution in the issuer.

Stakeholder Impact

• Shareholders of Tarsus Pharmaceuticals Inc. should understand that while The Vanguard Group, Inc. itself no longer reports beneficial ownership, this is due to an internal realignment and disaggregated reporting by its subsidiaries, not necessarily a divestment by the broader Vanguard organization.

Key Dates

Keywords

Tarsus Pharmaceuticals, Vanguard Group, Schedule 13G, beneficial ownership, SEC filing, institutional ownership, common stock, realignment